These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Immunotherapy in multiple sclerosis, Part 1. Becker CC; Gidal BE; Fleming JO Am J Health Syst Pharm; 1995 Sep; 52(18):1985-2000. PubMed ID: 8528866 [TBL] [Abstract][Full Text] [Related]
6. Multiple sclerosis, relapses, and the mechanism of action of adrenocorticotropic hormone. Ross AP; Ben-Zacharia A; Harris C; Smrtka J Front Neurol; 2013; 4():21. PubMed ID: 23482896 [TBL] [Abstract][Full Text] [Related]
7. Mechanisms of action of adrenocorticotropic hormone and other melanocortins relevant to the clinical management of patients with multiple sclerosis. Arnason BG; Berkovich R; Catania A; Lisak RP; Zaidi M Mult Scler; 2013 Feb; 19(2):130-6. PubMed ID: 23034287 [TBL] [Abstract][Full Text] [Related]
9. Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis. Filippini G; Del Giovane C; Vacchi L; D'Amico R; Di Pietrantonj C; Beecher D; Salanti G Cochrane Database Syst Rev; 2013 Jun; 2013(6):CD008933. PubMed ID: 23744561 [TBL] [Abstract][Full Text] [Related]
10. Long term effects of corticosteroids in multiple sclerosis in terms of the "no evidence of disease activity" (NEDA) domains. Saied A; Elsaid N; Azab A Steroids; 2019 Sep; 149():108401. PubMed ID: 31100292 [TBL] [Abstract][Full Text] [Related]
11. Multiple sclerosis: a review of existing therapy and future prospects. Khan OA J Pak Med Assoc; 1996 Jan; 46(1):20-4. PubMed ID: 8830165 [TBL] [Abstract][Full Text] [Related]
12. [Therapeutic indications for acute episodes of multiple sclerosis]. Brochet B Rev Neurol (Paris); 2001 Sep; 157(8-9 Pt 2):988-95. PubMed ID: 11787365 [TBL] [Abstract][Full Text] [Related]
13. Mitoxantrone: a review of its use in multiple sclerosis. Scott LJ; Figgitt DP CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110 [TBL] [Abstract][Full Text] [Related]
14. Immunotherapy of multiple sclerosis: the state of the art. Karussis D BioDrugs; 2013 Apr; 27(2):113-48. PubMed ID: 23423844 [TBL] [Abstract][Full Text] [Related]
15. Repository corticotropin injection improves quality metrics in an observational study of multiple sclerosis relapse. Kaplan J; Miller T; Baker M; Due B; Zhao E Neurodegener Dis Manag; 2021 Dec; 11(6):469-476. PubMed ID: 34860120 [TBL] [Abstract][Full Text] [Related]
16. Corticotropin is superior to corticosteroids in the treatment of MS. Poser CM Arch Neurol; 1989 Sep; 46(9):946. PubMed ID: 2549925 [No Abstract] [Full Text] [Related]
17. Corticosteroids in the management of acute multiple sclerosis exacerbations. Smets I; Van Deun L; Bohyn C; van Pesch V; Vanopdenbosch L; Dive D; Bissay V; Dubois B; Acta Neurol Belg; 2017 Sep; 117(3):623-633. PubMed ID: 28391390 [TBL] [Abstract][Full Text] [Related]
18. Corticosteroids for multiple sclerosis: I. Application for treating exacerbations. Frohman EM; Shah A; Eggenberger E; Metz L; Zivadinov R; Stüve O Neurotherapeutics; 2007 Oct; 4(4):618-26. PubMed ID: 17920542 [TBL] [Abstract][Full Text] [Related]
19. Variation of serum uric acid levels in multiple sclerosis during relapses and immunomodulatory treatment. Guerrero AL; Martín-Polo J; Laherrán E; Gutiérrez F; Iglesias F; Tejero MA; Rodríguez-Gallego M; Alcázar C Eur J Neurol; 2008 Apr; 15(4):394-7. PubMed ID: 18312403 [TBL] [Abstract][Full Text] [Related]
20. A meta-analysis of the efficacy and tolerability of interferon-β in multiple sclerosis, overall and by drug and disease type. Nikfar S; Rahimi R; Abdollahi M Clin Ther; 2010 Oct; 32(11):1871-88. PubMed ID: 21095482 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]